U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C25H31NO6
Molecular Weight 441.5167
Optical Activity UNSPECIFIED
Defined Stereocenters 8 / 8
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of DEFLAZACORT

SMILES

[H][C@@]12C[C@@]3([H])[C@]4([H])CCC5=CC(=O)C=C[C@]5(C)[C@@]4([H])[C@@H](O)C[C@]3(C)[C@@]1(N=C(C)O2)C(=O)COC(C)=O

InChI

InChIKey=FBHSPRKOSMHSIF-GRMWVWQJSA-N
InChI=1S/C25H31NO6/c1-13-26-25(20(30)12-31-14(2)27)21(32-13)10-18-17-6-5-15-9-16(28)7-8-23(15,3)22(17)19(29)11-24(18,25)4/h7-9,17-19,21-22,29H,5-6,10-12H2,1-4H3/t17-,18-,19-,21+,22+,23-,24-,25+/m0/s1

HIDE SMILES / InChI
Molecular Formula C25H31NO6
Molecular Weight 441.5167
Charge 0
Count
Stereochemistry ABSOLUTE
Additional Stereochemistry No
Defined Stereocenters 7 / 8
E/Z Centers 0
Optical Activity UNSPECIFIED

Description
Curator's Comment: description was created based on several sources, including, http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2763756/

Deflazacort is a glucocorticoid developed for the treatment of different inflammatory and immune conditions. The drug is rapidly metabolized to an active metabolite, 21-hydroxy-deflazaxort that may cross the blood brain barrier. Deflazacort acts by suppressing inflammatory response.

CNS Activity

CNS Penetrant
2554
Sources: www.ncbi.nlm.nih.gov/pubmed/10229911
Curator's Comment: Deflazacort active metabolite, 21-hydroxy-deflazacort crosses the blood-brain barrier in very low concentrations.

Approval Year

2017
422
Targets

Targets

Primary TargetPharmacologyConditionPotency
Inhibitor
8297
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
Approved
8429
CALCORT

Approved Use

Treat inflammation including asthma, arthritis and allergies; treat problems with skin, kidney, heart, digestive system, eyes or blood, treat problems where body has growths (tumours), suppress the immune system in transplant operations.
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
381 ng/mL
DRUG LABEL
https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/208684s000,208685s000lbl.pdf
0.9 mg/kg single, oral
dose: 0.9 mg/kg
route of administration: Oral
experiment type: SINGLE
co-administered:
21-DESACETYLDEFLAZACORT plasma
Homo sapiens
population: UNHEALTHY
age: ADOLESCENT
sex: UNKNOWN
food status: UNKNOWN
206 ng/mL
DRUG LABEL
https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/208684s000,208685s000lbl.pdf
0.9 mg/kg single, oral
dose: 0.9 mg/kg
route of administration: Oral
experiment type: SINGLE
co-administered:
21-DESACETYLDEFLAZACORT plasma
Homo sapiens
population: UNHEALTHY
age: CHILD
sex: UNKNOWN
food status: UNKNOWN
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
655 ng × h/mL
DRUG LABEL
https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/208684s000,208685s000lbl.pdf
0.9 mg/kg single, oral
dose: 0.9 mg/kg
route of administration: Oral
experiment type: SINGLE
co-administered:
21-DESACETYLDEFLAZACORT plasma
Homo sapiens
population: UNHEALTHY
age: ADOLESCENT
sex: UNKNOWN
food status: UNKNOWN
400 ng × h/mL
DRUG LABEL
https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/208684s000,208685s000lbl.pdf
0.9 mg/kg single, oral
dose: 0.9 mg/kg
route of administration: Oral
experiment type: SINGLE
co-administered:
21-DESACETYLDEFLAZACORT plasma
Homo sapiens
population: UNHEALTHY
age: CHILD
sex: UNKNOWN
food status: UNKNOWN
Funbound

Funbound

ValueDoseCo-administeredAnalytePopulation
60%
DRUG LABEL
https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/208684s000,208685s000lbl.pdf
0.9 mg/kg single, oral
dose: 0.9 mg/kg
route of administration: Oral
experiment type: SINGLE
co-administered:
21-DESACETYLDEFLAZACORT plasma
Homo sapiens
population: UNHEALTHY
age: ADOLESCENT
sex: UNKNOWN
food status: UNKNOWN
Doses

Doses

DosePopulationAdverse events​
1.2 mg/kg 1 times / day multiple, oral
Higher than recommended
Dose: 1.2 mg/kg, 1 times / day
Route: oral
Route: multiple
Dose: 1.2 mg/kg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/208684s000,208685s000lbl.pdf
Page: 6.1
unhealthy, 5 - 15 years
Health Status: unhealthy
Condition: Duchenne muscular dystrophy
Age Group: 5 - 15 years
Sex: unknown
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/208684s000,208685s000lbl.pdf
Page: 6.1
Other AEs: Cushingoid, Erythema...
Other AEs:
Cushingoid (69%)
Erythema (49%)
Hirsutism (37%)
Headache (34%)
Weight increased (32%)
Constipation (15%)
Abdominal pain upper (14%)
Skin striae (11%)
Acne (11%)
Abdominal discomfort (8%)
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/208684s000,208685s000lbl.pdf
Page: 6.1
0.9 mg/kg 1 times / day multiple, oral
Recommended
Dose: 0.9 mg/kg, 1 times / day
Route: oral
Route: multiple
Dose: 0.9 mg/kg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/208684s000,208685s000lbl.pdf
Page: Table 1
unhealthy, 5 - 15 years
n = 51
Health Status: unhealthy
Condition: Duchenne muscular dystrophy
Age Group: 5 - 15 years
Sex: unknown
Population Size: 51
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/208684s000,208685s000lbl.pdf
Page: Table 1
Other AEs: Cushingoid, Weight increased...
Other AEs:
Cushingoid (33%)
Weight increased (20%)
Increased appetite (14%)
Upper respiratory tract infection (12%)
Cough (12%)
Pollakiuria (12%)
Nasopharyngitis (10%)
Hirsutism (10%)
Central obesity (10%)
Erythema (8%)
Irritability (8%)
Rhinorrhea (8%)
Abdominal discomfort (6%)
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/208684s000,208685s000lbl.pdf
Page: Table 1
0.9 mg/kg 1 times / day multiple, oral
Recommended
Dose: 0.9 mg/kg, 1 times / day
Route: oral
Route: multiple
Dose: 0.9 mg/kg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/208684s000,208685s000lbl.pdf
Page: Table 1
unhealthy, 5 - 15 years
n = 51
Health Status: unhealthy
Condition: Duchenne muscular dystrophy
Age Group: 5 - 15 years
Sex: unknown
Population Size: 51
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/208684s000,208685s000lbl.pdf
Page: Table 1
Other AEs: Cushingoid, Hirsutism...
Other AEs:
Cushingoid (60%)
Hirsutism (35%)
Weight increased (28%)
Erythema (28%)
Central obesity (25%)
Abdominal pain (18%)
Pollakiuria (15%)
Constipation (10%)
Irritability (10%)
Abnormal behavior (9%)
Pyrexia (9%)
Back pain (7%)
Rash (7%)
Contusion (6%)
Nausea (6%)
Psychomotor hyperactivity (6%)
Epistaxis (6%)
Skin striae (6%)
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/208684s000,208685s000lbl.pdf
Page: Table 1
AEs

AEs

AESignificanceDosePopulation
Acne 11%
1.2 mg/kg 1 times / day multiple, oral
Higher than recommended
Dose: 1.2 mg/kg, 1 times / day
Route: oral
Route: multiple
Dose: 1.2 mg/kg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/208684s000,208685s000lbl.pdf
Page: 6.1
unhealthy, 5 - 15 years
Health Status: unhealthy
Condition: Duchenne muscular dystrophy
Age Group: 5 - 15 years
Sex: unknown
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/208684s000,208685s000lbl.pdf
Page: 6.1
Skin striae 11%
1.2 mg/kg 1 times / day multiple, oral
Higher than recommended
Dose: 1.2 mg/kg, 1 times / day
Route: oral
Route: multiple
Dose: 1.2 mg/kg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/208684s000,208685s000lbl.pdf
Page: 6.1
unhealthy, 5 - 15 years
Health Status: unhealthy
Condition: Duchenne muscular dystrophy
Age Group: 5 - 15 years
Sex: unknown
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/208684s000,208685s000lbl.pdf
Page: 6.1
Abdominal pain upper 14%
1.2 mg/kg 1 times / day multiple, oral
Higher than recommended
Dose: 1.2 mg/kg, 1 times / day
Route: oral
Route: multiple
Dose: 1.2 mg/kg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/208684s000,208685s000lbl.pdf
Page: 6.1
unhealthy, 5 - 15 years
Health Status: unhealthy
Condition: Duchenne muscular dystrophy
Age Group: 5 - 15 years
Sex: unknown
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/208684s000,208685s000lbl.pdf
Page: 6.1
Constipation 15%
1.2 mg/kg 1 times / day multiple, oral
Higher than recommended
Dose: 1.2 mg/kg, 1 times / day
Route: oral
Route: multiple
Dose: 1.2 mg/kg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/208684s000,208685s000lbl.pdf
Page: 6.1
unhealthy, 5 - 15 years
Health Status: unhealthy
Condition: Duchenne muscular dystrophy
Age Group: 5 - 15 years
Sex: unknown
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/208684s000,208685s000lbl.pdf
Page: 6.1
Weight increased 32%
1.2 mg/kg 1 times / day multiple, oral
Higher than recommended
Dose: 1.2 mg/kg, 1 times / day
Route: oral
Route: multiple
Dose: 1.2 mg/kg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/208684s000,208685s000lbl.pdf
Page: 6.1
unhealthy, 5 - 15 years
Health Status: unhealthy
Condition: Duchenne muscular dystrophy
Age Group: 5 - 15 years
Sex: unknown
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/208684s000,208685s000lbl.pdf
Page: 6.1
Headache 34%
1.2 mg/kg 1 times / day multiple, oral
Higher than recommended
Dose: 1.2 mg/kg, 1 times / day
Route: oral
Route: multiple
Dose: 1.2 mg/kg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/208684s000,208685s000lbl.pdf
Page: 6.1
unhealthy, 5 - 15 years
Health Status: unhealthy
Condition: Duchenne muscular dystrophy
Age Group: 5 - 15 years
Sex: unknown
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/208684s000,208685s000lbl.pdf
Page: 6.1
Hirsutism 37%
1.2 mg/kg 1 times / day multiple, oral
Higher than recommended
Dose: 1.2 mg/kg, 1 times / day
Route: oral
Route: multiple
Dose: 1.2 mg/kg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/208684s000,208685s000lbl.pdf
Page: 6.1
unhealthy, 5 - 15 years
Health Status: unhealthy
Condition: Duchenne muscular dystrophy
Age Group: 5 - 15 years
Sex: unknown
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/208684s000,208685s000lbl.pdf
Page: 6.1
Erythema 49%
1.2 mg/kg 1 times / day multiple, oral
Higher than recommended
Dose: 1.2 mg/kg, 1 times / day
Route: oral
Route: multiple
Dose: 1.2 mg/kg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/208684s000,208685s000lbl.pdf
Page: 6.1
unhealthy, 5 - 15 years
Health Status: unhealthy
Condition: Duchenne muscular dystrophy
Age Group: 5 - 15 years
Sex: unknown
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/208684s000,208685s000lbl.pdf
Page: 6.1
Cushingoid 69%
1.2 mg/kg 1 times / day multiple, oral
Higher than recommended
Dose: 1.2 mg/kg, 1 times / day
Route: oral
Route: multiple
Dose: 1.2 mg/kg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/208684s000,208685s000lbl.pdf
Page: 6.1
unhealthy, 5 - 15 years
Health Status: unhealthy
Condition: Duchenne muscular dystrophy
Age Group: 5 - 15 years
Sex: unknown
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/208684s000,208685s000lbl.pdf
Page: 6.1
Abdominal discomfort 8%
1.2 mg/kg 1 times / day multiple, oral
Higher than recommended
Dose: 1.2 mg/kg, 1 times / day
Route: oral
Route: multiple
Dose: 1.2 mg/kg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/208684s000,208685s000lbl.pdf
Page: 6.1
unhealthy, 5 - 15 years
Health Status: unhealthy
Condition: Duchenne muscular dystrophy
Age Group: 5 - 15 years
Sex: unknown
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/208684s000,208685s000lbl.pdf
Page: 6.1
Central obesity 10%
0.9 mg/kg 1 times / day multiple, oral
Recommended
Dose: 0.9 mg/kg, 1 times / day
Route: oral
Route: multiple
Dose: 0.9 mg/kg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/208684s000,208685s000lbl.pdf
Page: Table 1
unhealthy, 5 - 15 years
n = 51
Health Status: unhealthy
Condition: Duchenne muscular dystrophy
Age Group: 5 - 15 years
Sex: unknown
Population Size: 51
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/208684s000,208685s000lbl.pdf
Page: Table 1
Hirsutism 10%
0.9 mg/kg 1 times / day multiple, oral
Recommended
Dose: 0.9 mg/kg, 1 times / day
Route: oral
Route: multiple
Dose: 0.9 mg/kg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/208684s000,208685s000lbl.pdf
Page: Table 1
unhealthy, 5 - 15 years
n = 51
Health Status: unhealthy
Condition: Duchenne muscular dystrophy
Age Group: 5 - 15 years
Sex: unknown
Population Size: 51
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/208684s000,208685s000lbl.pdf
Page: Table 1
Nasopharyngitis 10%
0.9 mg/kg 1 times / day multiple, oral
Recommended
Dose: 0.9 mg/kg, 1 times / day
Route: oral
Route: multiple
Dose: 0.9 mg/kg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/208684s000,208685s000lbl.pdf
Page: Table 1
unhealthy, 5 - 15 years
n = 51
Health Status: unhealthy
Condition: Duchenne muscular dystrophy
Age Group: 5 - 15 years
Sex: unknown
Population Size: 51
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/208684s000,208685s000lbl.pdf
Page: Table 1
Cough 12%
0.9 mg/kg 1 times / day multiple, oral
Recommended
Dose: 0.9 mg/kg, 1 times / day
Route: oral
Route: multiple
Dose: 0.9 mg/kg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/208684s000,208685s000lbl.pdf
Page: Table 1
unhealthy, 5 - 15 years
n = 51
Health Status: unhealthy
Condition: Duchenne muscular dystrophy
Age Group: 5 - 15 years
Sex: unknown
Population Size: 51
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/208684s000,208685s000lbl.pdf
Page: Table 1
Pollakiuria 12%
0.9 mg/kg 1 times / day multiple, oral
Recommended
Dose: 0.9 mg/kg, 1 times / day
Route: oral
Route: multiple
Dose: 0.9 mg/kg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/208684s000,208685s000lbl.pdf
Page: Table 1
unhealthy, 5 - 15 years
n = 51
Health Status: unhealthy
Condition: Duchenne muscular dystrophy
Age Group: 5 - 15 years
Sex: unknown
Population Size: 51
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/208684s000,208685s000lbl.pdf
Page: Table 1
Upper respiratory tract infection 12%
0.9 mg/kg 1 times / day multiple, oral
Recommended
Dose: 0.9 mg/kg, 1 times / day
Route: oral
Route: multiple
Dose: 0.9 mg/kg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/208684s000,208685s000lbl.pdf
Page: Table 1
unhealthy, 5 - 15 years
n = 51
Health Status: unhealthy
Condition: Duchenne muscular dystrophy
Age Group: 5 - 15 years
Sex: unknown
Population Size: 51
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/208684s000,208685s000lbl.pdf
Page: Table 1
Increased appetite 14%
0.9 mg/kg 1 times / day multiple, oral
Recommended
Dose: 0.9 mg/kg, 1 times / day
Route: oral
Route: multiple
Dose: 0.9 mg/kg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/208684s000,208685s000lbl.pdf
Page: Table 1
unhealthy, 5 - 15 years
n = 51
Health Status: unhealthy
Condition: Duchenne muscular dystrophy
Age Group: 5 - 15 years
Sex: unknown
Population Size: 51
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/208684s000,208685s000lbl.pdf
Page: Table 1
Weight increased 20%
0.9 mg/kg 1 times / day multiple, oral
Recommended
Dose: 0.9 mg/kg, 1 times / day
Route: oral
Route: multiple
Dose: 0.9 mg/kg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/208684s000,208685s000lbl.pdf
Page: Table 1
unhealthy, 5 - 15 years
n = 51
Health Status: unhealthy
Condition: Duchenne muscular dystrophy
Age Group: 5 - 15 years
Sex: unknown
Population Size: 51
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/208684s000,208685s000lbl.pdf
Page: Table 1
Cushingoid 33%
0.9 mg/kg 1 times / day multiple, oral
Recommended
Dose: 0.9 mg/kg, 1 times / day
Route: oral
Route: multiple
Dose: 0.9 mg/kg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/208684s000,208685s000lbl.pdf
Page: Table 1
unhealthy, 5 - 15 years
n = 51
Health Status: unhealthy
Condition: Duchenne muscular dystrophy
Age Group: 5 - 15 years
Sex: unknown
Population Size: 51
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/208684s000,208685s000lbl.pdf
Page: Table 1
Abdominal discomfort 6%
0.9 mg/kg 1 times / day multiple, oral
Recommended
Dose: 0.9 mg/kg, 1 times / day
Route: oral
Route: multiple
Dose: 0.9 mg/kg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/208684s000,208685s000lbl.pdf
Page: Table 1
unhealthy, 5 - 15 years
n = 51
Health Status: unhealthy
Condition: Duchenne muscular dystrophy
Age Group: 5 - 15 years
Sex: unknown
Population Size: 51
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/208684s000,208685s000lbl.pdf
Page: Table 1
Erythema 8%
0.9 mg/kg 1 times / day multiple, oral
Recommended
Dose: 0.9 mg/kg, 1 times / day
Route: oral
Route: multiple
Dose: 0.9 mg/kg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/208684s000,208685s000lbl.pdf
Page: Table 1
unhealthy, 5 - 15 years
n = 51
Health Status: unhealthy
Condition: Duchenne muscular dystrophy
Age Group: 5 - 15 years
Sex: unknown
Population Size: 51
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/208684s000,208685s000lbl.pdf
Page: Table 1
Irritability 8%
0.9 mg/kg 1 times / day multiple, oral
Recommended
Dose: 0.9 mg/kg, 1 times / day
Route: oral
Route: multiple
Dose: 0.9 mg/kg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/208684s000,208685s000lbl.pdf
Page: Table 1
unhealthy, 5 - 15 years
n = 51
Health Status: unhealthy
Condition: Duchenne muscular dystrophy
Age Group: 5 - 15 years
Sex: unknown
Population Size: 51
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/208684s000,208685s000lbl.pdf
Page: Table 1
Rhinorrhea 8%
0.9 mg/kg 1 times / day multiple, oral
Recommended
Dose: 0.9 mg/kg, 1 times / day
Route: oral
Route: multiple
Dose: 0.9 mg/kg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/208684s000,208685s000lbl.pdf
Page: Table 1
unhealthy, 5 - 15 years
n = 51
Health Status: unhealthy
Condition: Duchenne muscular dystrophy
Age Group: 5 - 15 years
Sex: unknown
Population Size: 51
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/208684s000,208685s000lbl.pdf
Page: Table 1
Constipation 10%
0.9 mg/kg 1 times / day multiple, oral
Recommended
Dose: 0.9 mg/kg, 1 times / day
Route: oral
Route: multiple
Dose: 0.9 mg/kg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/208684s000,208685s000lbl.pdf
Page: Table 1
unhealthy, 5 - 15 years
n = 51
Health Status: unhealthy
Condition: Duchenne muscular dystrophy
Age Group: 5 - 15 years
Sex: unknown
Population Size: 51
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/208684s000,208685s000lbl.pdf
Page: Table 1
Irritability 10%
0.9 mg/kg 1 times / day multiple, oral
Recommended
Dose: 0.9 mg/kg, 1 times / day
Route: oral
Route: multiple
Dose: 0.9 mg/kg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/208684s000,208685s000lbl.pdf
Page: Table 1
unhealthy, 5 - 15 years
n = 51
Health Status: unhealthy
Condition: Duchenne muscular dystrophy
Age Group: 5 - 15 years
Sex: unknown
Population Size: 51
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/208684s000,208685s000lbl.pdf
Page: Table 1
Pollakiuria 15%
0.9 mg/kg 1 times / day multiple, oral
Recommended
Dose: 0.9 mg/kg, 1 times / day
Route: oral
Route: multiple
Dose: 0.9 mg/kg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/208684s000,208685s000lbl.pdf
Page: Table 1
unhealthy, 5 - 15 years
n = 51
Health Status: unhealthy
Condition: Duchenne muscular dystrophy
Age Group: 5 - 15 years
Sex: unknown
Population Size: 51
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/208684s000,208685s000lbl.pdf
Page: Table 1
Abdominal pain 18%
0.9 mg/kg 1 times / day multiple, oral
Recommended
Dose: 0.9 mg/kg, 1 times / day
Route: oral
Route: multiple
Dose: 0.9 mg/kg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/208684s000,208685s000lbl.pdf
Page: Table 1
unhealthy, 5 - 15 years
n = 51
Health Status: unhealthy
Condition: Duchenne muscular dystrophy
Age Group: 5 - 15 years
Sex: unknown
Population Size: 51
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/208684s000,208685s000lbl.pdf
Page: Table 1
Central obesity 25%
0.9 mg/kg 1 times / day multiple, oral
Recommended
Dose: 0.9 mg/kg, 1 times / day
Route: oral
Route: multiple
Dose: 0.9 mg/kg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/208684s000,208685s000lbl.pdf
Page: Table 1
unhealthy, 5 - 15 years
n = 51
Health Status: unhealthy
Condition: Duchenne muscular dystrophy
Age Group: 5 - 15 years
Sex: unknown
Population Size: 51
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/208684s000,208685s000lbl.pdf
Page: Table 1
Erythema 28%
0.9 mg/kg 1 times / day multiple, oral
Recommended
Dose: 0.9 mg/kg, 1 times / day
Route: oral
Route: multiple
Dose: 0.9 mg/kg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/208684s000,208685s000lbl.pdf
Page: Table 1
unhealthy, 5 - 15 years
n = 51
Health Status: unhealthy
Condition: Duchenne muscular dystrophy
Age Group: 5 - 15 years
Sex: unknown
Population Size: 51
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/208684s000,208685s000lbl.pdf
Page: Table 1
Weight increased 28%
0.9 mg/kg 1 times / day multiple, oral
Recommended
Dose: 0.9 mg/kg, 1 times / day
Route: oral
Route: multiple
Dose: 0.9 mg/kg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/208684s000,208685s000lbl.pdf
Page: Table 1
unhealthy, 5 - 15 years
n = 51
Health Status: unhealthy
Condition: Duchenne muscular dystrophy
Age Group: 5 - 15 years
Sex: unknown
Population Size: 51
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/208684s000,208685s000lbl.pdf
Page: Table 1
Hirsutism 35%
0.9 mg/kg 1 times / day multiple, oral
Recommended
Dose: 0.9 mg/kg, 1 times / day
Route: oral
Route: multiple
Dose: 0.9 mg/kg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/208684s000,208685s000lbl.pdf
Page: Table 1
unhealthy, 5 - 15 years
n = 51
Health Status: unhealthy
Condition: Duchenne muscular dystrophy
Age Group: 5 - 15 years
Sex: unknown
Population Size: 51
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/208684s000,208685s000lbl.pdf
Page: Table 1
Contusion 6%
0.9 mg/kg 1 times / day multiple, oral
Recommended
Dose: 0.9 mg/kg, 1 times / day
Route: oral
Route: multiple
Dose: 0.9 mg/kg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/208684s000,208685s000lbl.pdf
Page: Table 1
unhealthy, 5 - 15 years
n = 51
Health Status: unhealthy
Condition: Duchenne muscular dystrophy
Age Group: 5 - 15 years
Sex: unknown
Population Size: 51
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/208684s000,208685s000lbl.pdf
Page: Table 1
Epistaxis 6%
0.9 mg/kg 1 times / day multiple, oral
Recommended
Dose: 0.9 mg/kg, 1 times / day
Route: oral
Route: multiple
Dose: 0.9 mg/kg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/208684s000,208685s000lbl.pdf
Page: Table 1
unhealthy, 5 - 15 years
n = 51
Health Status: unhealthy
Condition: Duchenne muscular dystrophy
Age Group: 5 - 15 years
Sex: unknown
Population Size: 51
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/208684s000,208685s000lbl.pdf
Page: Table 1
Nausea 6%
0.9 mg/kg 1 times / day multiple, oral
Recommended
Dose: 0.9 mg/kg, 1 times / day
Route: oral
Route: multiple
Dose: 0.9 mg/kg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/208684s000,208685s000lbl.pdf
Page: Table 1
unhealthy, 5 - 15 years
n = 51
Health Status: unhealthy
Condition: Duchenne muscular dystrophy
Age Group: 5 - 15 years
Sex: unknown
Population Size: 51
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/208684s000,208685s000lbl.pdf
Page: Table 1
Psychomotor hyperactivity 6%
0.9 mg/kg 1 times / day multiple, oral
Recommended
Dose: 0.9 mg/kg, 1 times / day
Route: oral
Route: multiple
Dose: 0.9 mg/kg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/208684s000,208685s000lbl.pdf
Page: Table 1
unhealthy, 5 - 15 years
n = 51
Health Status: unhealthy
Condition: Duchenne muscular dystrophy
Age Group: 5 - 15 years
Sex: unknown
Population Size: 51
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/208684s000,208685s000lbl.pdf
Page: Table 1
Skin striae 6%
0.9 mg/kg 1 times / day multiple, oral
Recommended
Dose: 0.9 mg/kg, 1 times / day
Route: oral
Route: multiple
Dose: 0.9 mg/kg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/208684s000,208685s000lbl.pdf
Page: Table 1
unhealthy, 5 - 15 years
n = 51
Health Status: unhealthy
Condition: Duchenne muscular dystrophy
Age Group: 5 - 15 years
Sex: unknown
Population Size: 51
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/208684s000,208685s000lbl.pdf
Page: Table 1
Cushingoid 60%
0.9 mg/kg 1 times / day multiple, oral
Recommended
Dose: 0.9 mg/kg, 1 times / day
Route: oral
Route: multiple
Dose: 0.9 mg/kg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/208684s000,208685s000lbl.pdf
Page: Table 1
unhealthy, 5 - 15 years
n = 51
Health Status: unhealthy
Condition: Duchenne muscular dystrophy
Age Group: 5 - 15 years
Sex: unknown
Population Size: 51
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/208684s000,208685s000lbl.pdf
Page: Table 1
Back pain 7%
0.9 mg/kg 1 times / day multiple, oral
Recommended
Dose: 0.9 mg/kg, 1 times / day
Route: oral
Route: multiple
Dose: 0.9 mg/kg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/208684s000,208685s000lbl.pdf
Page: Table 1
unhealthy, 5 - 15 years
n = 51
Health Status: unhealthy
Condition: Duchenne muscular dystrophy
Age Group: 5 - 15 years
Sex: unknown
Population Size: 51
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/208684s000,208685s000lbl.pdf
Page: Table 1
Rash 7%
0.9 mg/kg 1 times / day multiple, oral
Recommended
Dose: 0.9 mg/kg, 1 times / day
Route: oral
Route: multiple
Dose: 0.9 mg/kg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/208684s000,208685s000lbl.pdf
Page: Table 1
unhealthy, 5 - 15 years
n = 51
Health Status: unhealthy
Condition: Duchenne muscular dystrophy
Age Group: 5 - 15 years
Sex: unknown
Population Size: 51
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/208684s000,208685s000lbl.pdf
Page: Table 1
Abnormal behavior 9%
0.9 mg/kg 1 times / day multiple, oral
Recommended
Dose: 0.9 mg/kg, 1 times / day
Route: oral
Route: multiple
Dose: 0.9 mg/kg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/208684s000,208685s000lbl.pdf
Page: Table 1
unhealthy, 5 - 15 years
n = 51
Health Status: unhealthy
Condition: Duchenne muscular dystrophy
Age Group: 5 - 15 years
Sex: unknown
Population Size: 51
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/208684s000,208685s000lbl.pdf
Page: Table 1
Pyrexia 9%
0.9 mg/kg 1 times / day multiple, oral
Recommended
Dose: 0.9 mg/kg, 1 times / day
Route: oral
Route: multiple
Dose: 0.9 mg/kg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/208684s000,208685s000lbl.pdf
Page: Table 1
unhealthy, 5 - 15 years
n = 51
Health Status: unhealthy
Condition: Duchenne muscular dystrophy
Age Group: 5 - 15 years
Sex: unknown
Population Size: 51
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/208684s000,208685s000lbl.pdf
Page: Table 1
Overview

Overview

CYP3A4CYP2C9CYP2D6hERG
substrate
1737

inhibitor
1587

inducer
781
inhibitor
1767
inhibitor
1852
inhibitor
1612

OverviewOther

Other InhibitorOther SubstrateOther Inducer
CYP1A2
1524

CYP2C19
1478

UGT1A1
204

UGT1A4
77

UGT1A6
108

UGT1A9
116

UGT2B7
146

CYP2B6
810

CYP2C8
911

UGT1A3
84

UGT2B15
64

P-gp
1461

BCRP
699

OATP1B1
788

OATP1B3
706

OAT1
599

OAT3
642

OCT2
647
esterase
72

P-gp
1537

BCRP
561

OATP1B1
406

OATP1B3
350
CYP1A2
701

CYP2B6
547
Drug as perpetrator​

Drug as perpetrator​

TargetModalityActivityMetaboliteClinical evidence
BCRP
773
 no
21-DESACETYLDEFLAZACORT
2
CYP1A2
1692
 no
21-DESACETYLDEFLAZACORT
2
CYP1A2
1692
 no
21-DESACETYLDEFLAZACORT
2
CYP2B6
1001
 no
21-DESACETYLDEFLAZACORT
2
CYP2C19
1553
 no
21-DESACETYLDEFLAZACORT
2
CYP2C9
1819
 no
21-DESACETYLDEFLAZACORT
2
CYP3A4
1925
 no
21-DESACETYLDEFLAZACORT
2
OAT1
603
 no
21-DESACETYLDEFLAZACORT
2
OAT3
644
 no
21-DESACETYLDEFLAZACORT
2
OATP1B1
803
 no
21-DESACETYLDEFLAZACORT
2
OATP1B3
715
 no
21-DESACETYLDEFLAZACORT
2
OCT2
648
 no
21-DESACETYLDEFLAZACORT
2
P-gp
1650
 no
21-DESACETYLDEFLAZACORT
2
UGT1A1
254
 no
21-DESACETYLDEFLAZACORT
2
UGT1A4
80
 no
21-DESACETYLDEFLAZACORT
2
UGT1A6
141
 no
21-DESACETYLDEFLAZACORT
2
UGT1A9
121
 no
21-DESACETYLDEFLAZACORT
2
UGT2B7
157
 no
21-DESACETYLDEFLAZACORT
2
CYP2B6
1001
 weak
21-DESACETYLDEFLAZACORT
2
CYP2C8
965
 weak
21-DESACETYLDEFLAZACORT
2
CYP2D6
1891
 weak
21-DESACETYLDEFLAZACORT
2
CYP3A4
1925
 weak
21-DESACETYLDEFLAZACORT
2
UGT1A3
93
 weak
21-DESACETYLDEFLAZACORT
2
UGT2B15
64
 weak
21-DESACETYLDEFLAZACORT
2
Drug as victim

Drug as victim

TargetModalityActivityMetaboliteClinical evidence
BCRP
561
 no
21-DESACETYLDEFLAZACORT
2
OATP1B1
406
 no
21-DESACETYLDEFLAZACORT
2
OATP1B3
350
 no
21-DESACETYLDEFLAZACORT
2
P-gp
1537
 yes
21-DESACETYLDEFLAZACORT
2
esterase
72
 yes
CYP3A4
1737
 yes
21-DESACETYLDEFLAZACORT
2
yes (co-administration study)
Comment: In a dedicated drug-drug interaction (DDI) study with multiple doses of clarithromycin, a strong CYP3A4 inhibitor, a 2 to 3 fold increase in Cmax, and AUCinf values of 21-des-DFZ was observed.
Page: 3.0
Tox targets

Tox targets

TargetModalityActivityMetaboliteClinical evidence
hERG
1647
21-DESACETYLDEFLAZACORT
2
PubMed

PubMed

TitleDatePubMed
Effectiveness of nifedipine and deflazacort in the management of distal ureter stones.
2000 Oct 1
Patents

Patents

JP2005519852A
24

Sample Use Guides

In Vivo Use Guide
The usual dose for most conditions, including rheumatoid arthritis is half to three tablets each day, the dose for severe asthma may be up to 8 or 12 tablets each day.
Route of Administration: Oral
In Vitro Use Guide
Phytohaemagglutinin stimulated peripheral blood lymphocytes, NK and K cells were incubated with different concentrations of the drug (0, 1.2, 6.0, 24, 60, 240, and 600 x 10(-7) M) and the immunosuppressive effect was measured. Deflazacort suppressed the cells in a dose dependent way.
Substance Class Chemical
Created
by admin
on Fri Dec 15 15:24:36 GMT 2023
Edited
by admin
on Fri Dec 15 15:24:36 GMT 2023
Record UNII
KR5YZ6AE4B
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
DEFLAZACORT
INN   MART.   MI   USAN   USP-RS   WHO-DD  
USAN   INN  
Official Name English
EMFLAZA
Brand Name English
DEFLAZACORT [USP-RS]
Common Name English
11.BETA.,21-DIHYDROXY-2'-METHYL-5'.BETA.H-PREGNA-1,4-DIENO(17,16-D)OXAZOLE-3,20-DIONE 21-ACETATE
Common Name English
DEFLAZACORT [MI]
Common Name English
Deflazacort [WHO-DD]
Common Name English
MDL-458
Code English
DEFLAZACORT [USAN]
Common Name English
DEFLAZACORT [ORANGE BOOK]
Common Name English
MDL458
Code English
deflazacort [INN]
Common Name English
5'H-PREGNA-1,4-DIENO(17,16-D)OXAZOLE-3,20-DIONE, 21-(ACETYLOXY)-11-HYDROXY-2'-METHYL-, (11.BETA.,16.BETA.)-
Common Name English
DEFLAZACORT [MART.]
Common Name English
Classification Tree Code System Code
NCI_THESAURUS C521
Created by admin on Fri Dec 15 15:24:37 GMT 2023 , Edited by admin on Fri Dec 15 15:24:37 GMT 2023
FDA ORPHAN DRUG 491715
Created by admin on Fri Dec 15 15:24:37 GMT 2023 , Edited by admin on Fri Dec 15 15:24:37 GMT 2023
FDA ORPHAN DRUG 315110
Created by admin on Fri Dec 15 15:24:37 GMT 2023 , Edited by admin on Fri Dec 15 15:24:37 GMT 2023
WHO-VATC QH02AB13
Created by admin on Fri Dec 15 15:24:37 GMT 2023 , Edited by admin on Fri Dec 15 15:24:37 GMT 2023
FDA ORPHAN DRUG 403413
Created by admin on Fri Dec 15 15:24:37 GMT 2023 , Edited by admin on Fri Dec 15 15:24:37 GMT 2023
WHO-ATC H02AB13
Created by admin on Fri Dec 15 15:24:37 GMT 2023 , Edited by admin on Fri Dec 15 15:24:37 GMT 2023
NDF-RT N0000175576
Created by admin on Fri Dec 15 15:24:37 GMT 2023 , Edited by admin on Fri Dec 15 15:24:37 GMT 2023
Code System Code Type Description
LACTMED
Deflazacort
Created by admin on Fri Dec 15 15:24:37 GMT 2023 , Edited by admin on Fri Dec 15 15:24:37 GMT 2023
PRIMARY
MERCK INDEX
m4135
Created by admin on Fri Dec 15 15:24:37 GMT 2023 , Edited by admin on Fri Dec 15 15:24:37 GMT 2023
PRIMARY Merck Index
EPA CompTox
DTXSID9020378
Created by admin on Fri Dec 15 15:24:37 GMT 2023 , Edited by admin on Fri Dec 15 15:24:37 GMT 2023
PRIMARY
RS_ITEM_NUM
1166116
Created by admin on Fri Dec 15 15:24:37 GMT 2023 , Edited by admin on Fri Dec 15 15:24:37 GMT 2023
PRIMARY
ECHA (EC/EINECS)
238-483-7
Created by admin on Fri Dec 15 15:24:37 GMT 2023 , Edited by admin on Fri Dec 15 15:24:37 GMT 2023
PRIMARY
DAILYMED
KR5YZ6AE4B
Created by admin on Fri Dec 15 15:24:37 GMT 2023 , Edited by admin on Fri Dec 15 15:24:37 GMT 2023
PRIMARY
DRUG BANK
DB11921
Created by admin on Fri Dec 15 15:24:37 GMT 2023 , Edited by admin on Fri Dec 15 15:24:37 GMT 2023
PRIMARY
WIKIPEDIA
Deflazacort
Created by admin on Fri Dec 15 15:24:37 GMT 2023 , Edited by admin on Fri Dec 15 15:24:37 GMT 2023
PRIMARY
FDA UNII
KR5YZ6AE4B
Created by admin on Fri Dec 15 15:24:37 GMT 2023 , Edited by admin on Fri Dec 15 15:24:37 GMT 2023
PRIMARY
ChEMBL
CHEMBL1201891
Created by admin on Fri Dec 15 15:24:37 GMT 2023 , Edited by admin on Fri Dec 15 15:24:37 GMT 2023
PRIMARY
INN
4323
Created by admin on Fri Dec 15 15:24:37 GMT 2023 , Edited by admin on Fri Dec 15 15:24:37 GMT 2023
PRIMARY
CAS
14484-47-0
Created by admin on Fri Dec 15 15:24:37 GMT 2023 , Edited by admin on Fri Dec 15 15:24:37 GMT 2023
PRIMARY
RXCUI
22396
Created by admin on Fri Dec 15 15:24:37 GMT 2023 , Edited by admin on Fri Dec 15 15:24:37 GMT 2023
PRIMARY RxNorm
NCI_THESAURUS
C87230
Created by admin on Fri Dec 15 15:24:37 GMT 2023 , Edited by admin on Fri Dec 15 15:24:37 GMT 2023
PRIMARY
DRUG CENTRAL
793
Created by admin on Fri Dec 15 15:24:37 GMT 2023 , Edited by admin on Fri Dec 15 15:24:37 GMT 2023
PRIMARY
PUBCHEM
189821
Created by admin on Fri Dec 15 15:24:37 GMT 2023 , Edited by admin on Fri Dec 15 15:24:37 GMT 2023
PRIMARY
SMS_ID
100000092093
Created by admin on Fri Dec 15 15:24:37 GMT 2023 , Edited by admin on Fri Dec 15 15:24:37 GMT 2023
PRIMARY
USAN
X-95
Created by admin on Fri Dec 15 15:24:37 GMT 2023 , Edited by admin on Fri Dec 15 15:24:37 GMT 2023
PRIMARY
EVMPD
SUB06943MIG
Created by admin on Fri Dec 15 15:24:37 GMT 2023 , Edited by admin on Fri Dec 15 15:24:37 GMT 2023
PRIMARY
MESH
C021988
Created by admin on Fri Dec 15 15:24:37 GMT 2023 , Edited by admin on Fri Dec 15 15:24:37 GMT 2023
PRIMARY
Related Record Type Details
PLASMA PROTEIN FRACTION (HUMAN)
BINDER->LIGAND
BINDING
MULTIDRUG RESISTANCE PROTEIN 1
TRANSPORTER -> SUBSTRATE
GLUCOCORTICOID RECEPTOR
TARGET -> INHIBITOR
CYTOCHROME P450 3A4
METABOLIC ENZYME -> INHIBITOR
- Co-administration of deflazacort with clarithromycin, a strong CYP3A4 inhibitor, increased total exposure to 21-desDFZ by about 3-fold. - Co-administration of deflazacort with rifampin, a strong CYP3A4 inducer, significantly decreased the exposure of 21-desDFZ.
Related Record Type Details
Structure of 21-DESACETYLDEFLAZACORT
METABOLITE ACTIVE -> PRODRUG
Structure of 6BETA-HYDROXY-21-DESACETYL DEFLAZACORT
METABOLITE INACTIVE -> PARENT
Related Record Type Details
Structure of 21-DESACETYLDEFLAZACORT
ACTIVE MOIETY
Name Property Type Amount Referenced Substance Defining Parameters References
Tmax PHARMACOKINETIC ORAL ADMINISTRATION

Biological Half-life PHARMACOKINETIC
NIH
NCATS
PRIVACY ACT
ACCESSIBILITY
DISCLAIMER
HHS VULNERABILITY DISCLOSURE
For language access assistance, contact the NCATS Public Information Officer
National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966